Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Change in Cash (2016 - 2025)

Rein Therapeutics (RNTX) has disclosed Change in Cash for 10 consecutive years, with -$833000.0 as the latest value for Q4 2025.

  • Quarterly Change in Cash rose 82.69% to -$833000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$9.6 million through Dec 2025, down 115.74% year-over-year, with the annual reading at -$9.6 million for FY2025, 115.74% down from the prior year.
  • Change in Cash for Q4 2025 was -$833000.0 at Rein Therapeutics, up from -$1.7 million in the prior quarter.
  • The five-year high for Change in Cash was $11.7 million in Q1 2021, with the low at -$8.5 million in Q2 2021.
  • Average Change in Cash over 5 years is -$221200.0, with a median of -$1.4 million recorded in 2023.
  • The sharpest move saw Change in Cash tumbled 397.89% in 2021, then surged 2907.82% in 2023.
  • Over 5 years, Change in Cash stood at -$4.0 million in 2021, then soared by 108.87% to $355000.0 in 2022, then skyrocketed by 1377.18% to $5.2 million in 2023, then tumbled by 191.76% to -$4.8 million in 2024, then skyrocketed by 82.69% to -$833000.0 in 2025.
  • According to Business Quant data, Change in Cash over the past three periods came in at -$833000.0, -$1.7 million, and -$1.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.